A comprehensive overview of promising biomarkers in stage II colorectal cancer

Pauline Parent; Romain Cohen; Elie Rassy; Magali Svrcek; Julien Taieb; Thierry André; Anthony Turpin

doi:10.1016/j.ctrv.2020.102059

A comprehensive overview of promising biomarkers in stage II colorectal cancer

Cancer Treat Rev. 2020 Aug:88:102059. doi: 10.1016/j.ctrv.2020.102059. Epub 2020 Jun 23.

Authors

Pauline Parent¹, Romain Cohen², Elie Rassy³, Magali Svrcek⁴, Julien Taieb⁵, Thierry André², Anthony Turpin⁶

Affiliations

¹ University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.
² Department of Medical Oncology, Hospital Saint Antoine, APHP, 184 Rue du Faubourg Saint-Antoine, 75012 Paris, France; Medical Oncology Department, CHU Lille, University of Lille, Lille, France.
³ Department of Medical Oncology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France; Department of Medical Oncology, Saint Joseph University, Faculty of Medicine, Rue de Damas, 17-5208 Beirut, Lebanon.
⁴ Medical Oncology Department, CHU Lille, University of Lille, Lille, France; Department of Pathology, Hospital Saint Antoine, APHP, 184 Rue du Faubourg Saint-Antoine, 75012 Paris, France.
⁵ Department of Gastroenterology and Gastrointestinal Oncology, Georges-Pompidou European Hospital, 20 Rue Leblanc, 75015 Paris, France; AP-HP, Sorbonne Paris Cité, University of Paris, 2 rue Albert Einstein, 75013 Paris, France.
⁶ University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France; Medical Oncology Department, CHU Lille, University of Lille, Lille, France; Department of Gastroenterology and Gastrointestinal Oncology, Georges-Pompidou European Hospital, 20 Rue Leblanc, 75015 Paris, France; AP-HP, Sorbonne Paris Cité, University of Paris, 2 rue Albert Einstein, 75013 Paris, France; Department of Medical Oncology, Claude Huriez Hospital, Rue Michel Polonovski, 59000 Lille, France. Electronic address: anthony.turpin@chru-lille.fr.

PMID: 32622273
DOI: 10.1016/j.ctrv.2020.102059

Abstract

Colon cancer (CC) has the highest incidence rate among gastrointestinal cancers and ranks the third in mortality among all cancers, which contributes to the current CC burden and constitutes a major public health issue. While therapeutic strategies for stage I, III, and IV CC are standardized, those for stage II CC remain debatable. The choice of adjuvant chemotherapy for patients with stage II CC depends on stage (pT4) and grade (high) of the disease, the presence of venous, perinervous, and/or lymphatic emboli, or the need of suboptimal surgery (tumor with initial occlusion or perforation needing emergency surgeries, <12 lymph nodes harvested). Several prognostic factors that have been validated in retrospective studies can potentially define a population of CC patients at low and high-risk for reccurence. The role of biomarkers is becoming increasingly important for the future personalized treatment options. We conducted a systematic overview of potential prognostic biomarkers with possible clinical implications in stage II CC.

Keywords: Adjuvant chemotherapy; Artificial intelligence; Carcinoembryonic antigen; Circulating Tumor DNA; Colorectal cancer; Immunoscore.

Publication types

Review

MeSH terms

Animals
Biomarkers, Tumor / analysis*
Biomarkers, Tumor / metabolism
Colorectal Neoplasms / diagnosis*
Colorectal Neoplasms / drug therapy
Colorectal Neoplasms / metabolism
Colorectal Neoplasms / pathology
Humans
Neoplasm Staging
Prognosis

Substances

Biomarkers, Tumor